Highly specific radiographic marker predates clinical diagnosis in progressive supranuclear palsy

被引:15
|
作者
Owens, Emily [1 ]
Krecke, Karl [2 ]
Ahlskog, J. E. [1 ]
Fealey, Robert [1 ]
Hassan, Anhar [1 ]
Josephs, Keith A. [1 ]
Klassen, Bryan [1 ]
Matsumoto, Joseph [1 ]
Bower, James [1 ]
机构
[1] Mayo Clin, Dept Neurol, 200 Second St SW, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Neuroradiol, 200 Second St SW, Rochester, MN 55905 USA
关键词
Progressive supranuclear palsy; Imaging; MRI; MULTIPLE SYSTEM ATROPHY; PARKINSONS-DISEASE; ROUTINE MRI; PONS RATIO; MIDBRAIN; DIFFERENTIATION; VARIANT; INDEX;
D O I
10.1016/j.parkreldis.2016.05.006
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: The diagnosis of progressive supranuclear palsy is often challenging early in the course of the disease, when clinical signs of the condition may be less apparent and patients do not clearly meet diagnostic criteria. In this study, we examine a potential radiographic marker in progressive supranuclear palsy, and assess the timing of its presence in relation to diagnosis. Methods: A retrospective review of patients fulfilling clinical research criteria for multiple system atrophy, Parkinson's disease, and progressive supranuclear palsy (total n = 75) was performed. Midbrain and pontine diameters, and the midbrain to pons ratio were calculated by a neuroradiologist blinded to the clinical diagnosis. The timing of the presence of a midbrain to pons ratio of less than or equal to 0.52 was assessed in the progressive supranuclear palsy group in reference to the time of diagnosis. Results: The midbrain to pons ratio was significantly reduced in the progressive supranuclear palsy cohort (p < 0.0001), and a midbrain to pons ratio of less than or equal to 0.52 was 100% specific for progressive supranuclear palsy. This radiologic sign predated the clinical diagnosis of progressive supranuclear palsy by a mean of 15 months (range 1-47 months) in 14 of 17 (82%) of patients in whom it was found. Conclusions: The midbrain to pons ratio is an easily applied and highly specific tool in the diagnosis of progressive supranuclear palsy, and is frequently present before the diagnosis is made. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:107 / 111
页数:5
相关论文
共 50 条
  • [21] The contribution of white matter changes to clinical phenotype in progressive supranuclear palsy
    Tepedino, Maria Francesca
    Diana, Francesco
    Abate, Filomena
    Avallone, Anna Rosa
    Caterino, Miriam
    Erro, Roberto
    Pellecchia, Maria Teresa
    Manara, Renzo
    Barone, Paolo
    Picillo, Marina
    JOURNAL OF NEUROLOGY, 2024, 271 (10) : 6866 - 6875
  • [22] Biomarkers of disease progression in progressive supranuclear palsy for use in clinical trials
    Marotta, Cassandra
    Sinclair, Benjamin
    O'Brien, Terence J.
    Vivash, Lucy
    BRAIN COMMUNICATIONS, 2025, 7 (01)
  • [23] Neuronal Correlates of Clinical Asymmetry in Progressive Supranuclear Palsy
    Amtage, Florian
    Hellwig, Sabine
    Kreft, Annabelle
    Spehl, Timo
    Glauche, Volkmar
    Winkler, Christian
    Rijntjes, Michel
    Hellwig, Bernhard
    Weiller, Cornelius
    Weber, Wolfgang A.
    Tuescher, Oliver
    Meyer, Philipp Tobias
    CLINICAL NUCLEAR MEDICINE, 2014, 39 (04) : 319 - 325
  • [24] Update on the Diagnosis and Management of Progressive Supranuclear Palsy
    Garrido A.
    Vilas D.
    Tolosa E.
    Current Geriatrics Reports, 2016, 5 (2) : 85 - 94
  • [25] Specificity and sensitivity of magnetic resonance imaging findings in the diagnosis of progressive supranuclear palsy
    Bacchi, Stephen
    Chim, Ivana
    Patel, Sandy
    JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 2018, 62 (01) : 21 - 31
  • [26] What Features Improve the Accuracy of the Clinical Diagnosis of Progressive Supranuclear Palsy-parkinsonism (PSP-P)?
    Williams, David R.
    Lees, Andrew J.
    MOVEMENT DISORDERS, 2010, 25 (03) : 357 - 362
  • [27] Early clinical features of patients with progressive supranuclear palsy with predominant cerebellar ataxia
    Kanazawa, Masato
    Tada, Mari
    Onodera, Osamu
    Takahashi, Hitoshi
    Nishizawa, Masatoyo
    Shimohata, Takayoshi
    PARKINSONISM & RELATED DISORDERS, 2013, 19 (12) : 1149 - 1151
  • [28] Pathophysiology, genetics, clinical features, diagnosis and therapeutic trials in progressive supranuclear palsy
    Bluett, Brent
    Litvan, Irene
    EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (03): : 253 - 265
  • [29] Clinical genetics of familial progressive supranuclear palsy
    Rojo, A
    Pernaute, RS
    Fontán, A
    Ruíz, PG
    Honnorat, J
    Lynch, T
    Chin, S
    Gonzalo, I
    Rábano, A
    Martínez, A
    Daniel, S
    Pramsteller, P
    Morris, H
    Wood, N
    Lees, A
    Tabernero, C
    Nyggard, T
    Jackson, AC
    Hanson, A
    de Yébenes, JG
    BRAIN, 1999, 122 : 1233 - 1245
  • [30] A clinical rating scale for progressive supranuclear palsy
    Golbe, Lawrence I.
    Ohman-Strickland, Pamela A.
    BRAIN, 2007, 130 : 1552 - 1565